Glutamate receptor expression in schizophrenic brain

Brain Research Reviews

Volumn 31, Issue 2-3, 2000, Pages 288-294

  Meador Woodruff, James H ^a   Healy, Daniel J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

AMPA receptor; Kainate receptor; NMDA receptor

Indexed keywords

AMPA RECEPTOR; GLUTAMATE RECEPTOR; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT;

AUTOPSY; BINDING SITE; BRAIN; BRAIN CORTEX; CONFERENCE PAPER; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HYPOTHESIS; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SAMPLE; SCHIZOPHRENIA;

ANIMALS; BRAIN; HUMANS; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA;

EID: 0034094628     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(99)00044-2     Document Type: Conference Paper

References (57)

1. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E. Jr., Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 16:1996;19-30.
2. Angrist B., Peselow E., Rubinstein M., Corwin J., Rotrosen J. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology. 78:1982;128-130.
3. Aparicio-Legarza M.I., Davis B., Hutson P.H., Reynolds G.P. Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci. Lett. 241:1998;143-146.
4. Beckers J.M., Stevens C.F. NMDA and non-NMDA receptors are co-localized at individual excitatory synapses in cultured rat hippocampus. Nature. 341:1989;230-233.
5. Breese C.R., Freedman R., Leonard S.S. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 674:1995;82-90.
6. Burnashev N., Monyer H., Seeburg P.H., Sakmann B. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron. 8:1992;189-198.
7. Carlsson M., Carlsson A. Schizophrenia: A subcortical neurotransmitter imbalance syndrome? Schizophrenia Bull. 16:1990;425-432.
8. Cascella N.G., Macciardi F., Cavallini C., Smeraldi E. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study. J. Neural Trans. 95:1994;105-111.
9. Creese I., Burt I.R., Synder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
10. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry. 148:1991;1474-1486.
11. Daw N.W., Stein P.S.G., Fox K. The role of NMDA receptors in information processing. Ann. Rev. Neurosci. 16:1993;207-222.
12. Deakin J.F.W., Slater P., Simpson M.D.C., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G.P., Cross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52:1989;1781-1786.
13. Durand G.M., Bennett M.V.L., Zukin R.S. Splice variants of the N-methyl-D-aspartate receptor NR1 identify domains involved in regulation of polyamines and protein kinase C. Proc. Natl. Acad. Sci. USA. 90:1993;6731-6735.
14. Eastwood S.L., Burnet P.W.J., Harrison P.J. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase-polymerase chain reaction (RT-PCR) study. Mol. Brain Res. 44:1997;92-98.
15. Eastwood S.L., Kerwin R.W., Harrison P.J. Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol. Psychiatry. 41:1997;636-643.
16. Eastwood S.L., McDonald B., Burnet P.W.J., Beckwith J.P., Kerwin R.W., Harrison P.J. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res. 29:1995;211-223.
17. Feinberg I. Cortical pruning and the development of schizophrenia. Schizophrenia Bull. 16:1990;567-568.
18. 3H]AMPA binding in postmortem human brain from psychotic subjects and controls: increases in caudate nucleus associated with suicide. Exp. Neurol. 121:1993;48-56.
19. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry. 152:1995;1213-1215.
20. Harrison P.J., McLaughlin D., Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337:1991;450-452.
21. Healy D.J., Haroutunian V., Powchik P., Davidson M., Davis K.L., Watson S.J., Meador-Woodruff J.H. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology. 19:1998;278-286.
22. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry. 169:1996;610-617.
23. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science. 252:1991;851-853.
24. Hollmann M., Heinemann S. Cloned glutamate receptors. Ann. Rev. Neurosci. 17:1994;31-108.
25. Humphries C., Mortimer A., Hirsch S., de Belleroche J. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuropharmacol. Neurotox. 7:1996;2051-2055.
26. Huntley G.W., Vickers J.C., Morrison J.H. Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease. Trends Neurosci. 17:1994;536-543.
27. Ishimaru M., Kurumaji A., Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry. 35:1994;84-95.
28. Janowsky D.S., El-Yousef K., Davis J.M., Sekerke H.J. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch. Gen. Psychiatry. 28:1973;185-191.
29. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry. 151:1994;1234-1236.
30. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
31. Kerwin R., Patel S., Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience. 39:1990;25-32.
32. Kishi A., Ohno M., Watanabe S. Spermidine, a polyamine site agonist, attenuates working memory deficits caused by blockade of hippocampal muscarinic receptors and mGluRs in rats. Brain Res. 793:1998;311-314.
33. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J. Neural Transm. 77:1989;231-236.
34. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
35. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
36. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433.
37. Lynch D.R., Anegawa N.J., Verdoorn T., Pritchett D.B. N-methyl-D-Aspartate receptors: Different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents. Mol. Pharmacol. 45:1994;540-545.
38. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150.
39. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
40. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
41. 3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci. Letters. 40:1983;245-250.
42. Noga J.T., Hyde T.M., Herman M.M., Spurney C.F., Bigelow L.B., Weinberger D.R., Kleinman J.E. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse. 27:1997;168-176.
43. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol. Brain Res. 56:1998;207-217.
44. Pin J.-P., Duvoisin R. The metabotropic glutamate receptors: Structure and functions. Neuropharmacology. 34:1995;1-26.
45. Porter R.H.P., Eastwood S.L., Harrison P.J. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 751:1997;217-231.
46. Rakic P., Bourgeois J.P., Goldman-Rakic P.S. Synaptic development of the cerebral cortex: implications for learning, memory, and mental illness. Prog. Brain Res. 102:1994;227-243.
47. Rodriguez-Paz J.M., Anantharam Y., Treistman S.N. Block of the N-methyl-D-aspartate receptor by phencyclidine-like drugs is influenced by alternative splicing. Neurosci. Lett. 190:1995;147-150.
48. Rosse R.B., Fay-McCarthy M., Kendrick K., Davis R.E., Deutsch S.I. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin. Neuropharmacology. 19:1996;444-450.
49. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
50. Simpson M.D.C., Slater P., Royston M.C., Deakin J.F.W. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Schizophrenia Res. 6:1992;41-48.
51. Sokolov B.P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics: evidence on reversible up-regulation of typical neuroleptics. J. Neurochem. 71:1998;2454-2564.
52. Toru M., Kurumaji A., Kumashiro S., Suga I., Takashima M., Nishikawa T. Excitatory amino acidergic neurones in chronic schizophrenic brain. Mol. Neuropharm. 2:1992;241-243.
53. van Kammen D.P., Boronow J.J. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int. Clin. Psychopharmacol. 3:1988;111-121.
54. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia III: a new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiatry. 45:1988;609-615.
55. Weissman A.D., Casanova M.F., Kleinman J.E., London E.D., De Souza E.B. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol. Psychiatry. 54:1991;41-54.
56. H.V. Wheal, A.M. Thomson, Excitatory Amino Acids and Synaptic Transmission (2nd ed.), Academic Press, New York, 1995.
57. Zipursky R.B., Lim K.O., Sullivan E.V., Brown B.W., Pfefferbaum A. Widespread cerebral grey matter volume deficits in schizophrenia. Arch. Gen. Psychiatry. 49:1992;195-205.